Eyepoint Pharmaceuticals presents updated DURAVYU data with new real world insights

Eyepoint Pharmaceuticals presents updated DURAVYU data with new real world insights
Eyepoint unveils DURAVYU data update

Eyepoint Pharmaceuticals introduced new and incremental results from four presentations at RetinaSociety2026, deepening the understanding of its DURAVYU treatment. The company unveiled additional Phase 3 LUGANO data, focused on vision, anatomical outcomes, treatment burden, and repeat dosing safety, as well as sharing mechanistic findings and real world patient insights.

This update is positioned to inform future clinical discussions and may influence broader adoption strategies for DURAVYU as more outcomes data becomes available.

Eyepoint previously announced LUGANO Phase 3 clinical trial results and shifted its attention to the LUCIA trial for wet AMD, according to company statements. The company also sent a team to New York to attend investor conferences and connect with industry leaders as reported earlier. These developments reflect Eyepoint's ongoing efforts to advance its product pipeline and expand industry engagement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.